In the ventral tegmental area, progestins' membrane-mediated actions for lordosis of hamsters and rats involve protein kinase A

Neuroendocrinology. 2006;84(6):405-14. doi: 10.1159/000100510. Epub 2007 Mar 13.

Abstract

Progestin-facilitated lordosis of hamsters and rats is enhanced by activation of dopamine type 1 (D1) or GABAA/benzodiazepine receptor complexes (GBRs) in the ventral tegmental area (VTA) and these effects involve G-proteins and second messengers, such as adenosine 3',5'-monophosphate (cAMP). We examined whether D1- and/or GBR-mediated increases in progestin-facilitated lordosis of female hamsters and rats involve the cAMP-dependent protein kinase, protein kinase A (PKA), in the VTA. In experiment 1, ovariectomized hamsters, primed with estradiol (E2; 10 microg at h 0) + progesterone (P; 100 microg at h 45), were first pre-tested for lordosis and motor behavior (h 48) and then infused with the PKA inhibitor, Rp-cAMP (100 ng/side), or vehicle. Thirty minutes later, hamsters were retested and then received infusions of the D1 agonist, SKF38393 (100 ng/side), the GBR agonist, muscimol (100 ng/side), or vehicle to the VTA. Hamsters were post-tested for lordosis and motor behavior 30 min later. In Experiment 2, ovariectomized rats, primed with E2 (10 microg at h 0), were first pre-tested for lordosis and then infused with Rp-cAMP (100 ng/side) or vehicle to the VTA at h 44. Immediately after testing, rats received infusions of SKF38393 (100 ng/side), muscimol (100 ng/side), or vehicle and were retested for lordosis. Rats were then infused with the neurosteroid, 5alpha-pregnan-3alpha-ol-20-one (3alpha,5alpha-THP; 100 or 200 ng/side), or beta-cyclodextrin vehicle and were post-tested for lordosis and motor behavior 10 and 60 min later. The enhancing effects of progestins or progestins plus D1 or GBR activation on lordosis of E2-primed hamsters and rats were blocked by the PKA inhibitor, Rp-cAMP. Thus, in the VTA, progestins' membrane actions involving D1 or GBRs are mediated, in part, by PKA.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine / pharmacology
  • Animals
  • Cortodoxone / analogs & derivatives
  • Cortodoxone / pharmacology
  • Cricetinae
  • Cyclic AMP / analogs & derivatives
  • Cyclic AMP / pharmacology
  • Cyclic AMP-Dependent Protein Kinases / drug effects
  • Cyclic AMP-Dependent Protein Kinases / metabolism*
  • Dopamine Agonists / pharmacology
  • Female
  • GABA Agonists / pharmacology
  • Muscimol / pharmacology
  • Ovariectomy
  • Posture / physiology*
  • Progestins / physiology*
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Long-Evans
  • Receptors, Dopamine / physiology
  • Receptors, GABA-A / physiology
  • Sexual Behavior, Animal / physiology*
  • Thionucleotides / pharmacology
  • Ventral Tegmental Area / physiology*

Substances

  • Dopamine Agonists
  • GABA Agonists
  • Progestins
  • Protein Kinase Inhibitors
  • Receptors, Dopamine
  • Receptors, GABA-A
  • Thionucleotides
  • dopamine-I receptor
  • adenosine-3',5'-cyclic phosphorothioate
  • Muscimol
  • 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine
  • tetrahydro-11-deoxycortisol
  • Cyclic AMP
  • Cyclic AMP-Dependent Protein Kinases
  • Cortodoxone